Application 210297
- Type
- ANDA
- Sponsor
- SANDOZ INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | CANAGLIFLOZIN | CANAGLIFLOZIN | TABLET; ORAL | 100MG | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| INVOKANA | CANAGLIFLOZIN | Janssen Pharmaceuticals, Inc. | b9057d3b-b104-4f09-8a61-c61ef9d4a3f3 | 2026-06-11 | Warnings, Adverse reactions | CANAGLIFLOZIN |
| INVOKANA | CANAGLIFLOZIN | Cardinal Health 107, LLC | 5f76e16f-0c24-454a-81af-4080b312c940 | 2026-02-17 | Warnings, Adverse reactions | CANAGLIFLOZIN |
| INVOKANA | CANAGLIFLOZIN | A-S Medication Solutions | 9679460c-55f7-4826-b55c-fe116f020358 | 2023-12-15 | Warnings, Adverse reactions | CANAGLIFLOZIN |
| INVOKANA | CANAGLIFLOZIN | A-S Medication Solutions | 8d5f892b-e4f3-4a9e-9a91-95e2fca34144 | 2023-12-15 | Warnings, Adverse reactions | CANAGLIFLOZIN |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents#
| Document | Submission type | Date |
|---|---|---|
| 65860 | ORIG | 2021-01-07 |